Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
CNS Drugs
Published in: CNS Drugs 7/2015

01-07-2015 | Review Article

Propofol: A Review of its Role in Pediatric Anesthesia and Sedation

Authors: Vidya Chidambaran, Andrew Costandi, Ajay D’Mello

Published in: CNS Drugs | Issue 7/2015

Login to get access

Abstract

Propofol is an intravenous agent used commonly for the induction and maintenance of anesthesia, procedural, and critical care sedation in children. The mechanisms of action on the central nervous system involve interactions at various neurotransmitter receptors, especially the gamma-aminobutyric acid A receptor. Approved for use in the USA by the Food and Drug Administration in 1989, its use for induction of anesthesia in children less than 3 years of age still remains off-label. Despite its wide use in pediatric anesthesia, there is conflicting literature about its safety and serious adverse effects in particular subsets of children. Particularly as children are not “little adults”, in this review, we emphasize the maturational aspects of propofol pharmacokinetics. Despite the myriad of propofol pharmacokinetic-pharmacodynamic studies and the ability to use allometrical scaling to smooth out differences due to size and age, there is no optimal model that can be used in target controlled infusion pumps for providing closed loop total intravenous anesthesia in children. As the commercial formulation of propofol is a nutrient-rich emulsion, the risk for bacterial contamination exists despite the Food and Drug Administration mandating addition of antimicrobial preservative, calling for manufacturers’ directions to discard open vials after 6 h. While propofol has advantages over inhalation anesthesia such as less postoperative nausea and emergence delirium in children, pain on injection remains a problem even with newer formulations. Propofol is known to depress mitochondrial function by its action as an uncoupling agent in oxidative phosphorylation. This has implications for children with mitochondrial diseases and the occurrence of propofol-related infusion syndrome, a rare but seriously life-threatening complication of propofol. At the time of this review, there is no direct evidence in humans for propofol-induced neurotoxicity to the infant brain; however, current concerns of neuroapoptosis in developing brains induced by propofol persist and continue to be a focus of research.
Literature
1.
Trapani G, Altomare C, Liso G, Sanna E, Biggio G. Propofol in anesthesia: mechanism of action, structure-activity relationships, and drug delivery. Curr Med Chem. 2000;7(2):249–71.PubMedCrossRef
2.
Borgeat A, Popovic V, Meier D, Schwander D. Comparison of propofol and thiopental/halothane for short-duration ENT surgical procedures in children. Anesth Analg. 1990;71(5):511–5.PubMedCrossRef
3.
Reed MD, Yamashita TS, Marx CM, Myers CM, Blumer JL. A pharmacokinetically based propofol dosing strategy for sedation of the critically ill, mechanically ventilated pediatric patient. Crit Care Med. 1996;24(9):1473–81.PubMedCrossRef
4.
5.
Angelini G, Ketzler JT, Coursin DB. Use of propofol and other nonbenzodiazepine sedatives in the intensive care unit. Crit Care Clinics. 2001;17(4):863–80.CrossRef
6.
7.
8.
Langley MS, Heel RC. Propofol: a review of its pharmacodynamic and pharmacokinetic properties and use as an intravenous anaesthetic. Drugs. 1988;35(4):334–72.PubMedCrossRef
9.
Fulton B, Sorkin EM. Propofol: an overview of its pharmacology and a review of its clinical efficacy in intensive care sedation. Drugs. 1995;50(4):636–57.PubMedCrossRef
10.
Thompson KA, Goodale DB. The recent development of propofol (DIPRIVAN). Intensive Care Med. 2000;26(Suppl 4):S400–4.PubMedCrossRef
11.
James R, Glen JB. Synthesis, biological evaluation, and preliminary structure-activity considerations of a series of alkylphenols as intravenous anesthetic agents. J Med Chem. 1980;23(12):1350–7.PubMedCrossRef
12.
Briggs LP, Clarke RS, Watkins J. An adverse reaction to the administration of disoprofol (Diprivan). Anaesthesia. 1982;37(11):1099–101.PubMedCrossRef
13.
Cummings GC, Dixon J, Kay NH, Windsor JP, Major E, Morgan M, et al. Dose requirements of ICI 35,868 (propofol, ‘Diprivan’) in a new formulation for induction of anaesthesia. Anaesthesia. 1984;39(12):1168–71.PubMedCrossRef
14.
15.
16.
17.
Larsen R, Beerhalter U, Erdkonig R, Larsen B. Injection pain from propofol-MCT–LCT in children. A comparison with propofol-LCT. Der Anaesth. 2001;50(9):676–8.CrossRef
18.
19.
20.
Sanna E, Mascia MP, Klein RL, Whiting PJ, Biggio G, Harris RA. Actions of the general anesthetic propofol on recombinant human GABAA receptors: influence of receptor subunits. J Pharmacol Exp Ther. 1995;274(1):353–60.PubMed
21.
Collins GG. Effects of the anaesthetic 2,6-diisopropylphenol on synaptic transmission in the rat olfactory cortex slice. Br J Pharmacol. 1988;95(3):939–49.PubMedCentralPubMedCrossRef
22.
Sieghart W. Structure and pharmacology of gamma-aminobutyric acidA receptor subtypes. Pharmacol Rev. 1995;47(2):181–234.PubMed
23.
Barnard EA, Skolnick P, Olsen RW, Mohler H, Sieghart W, Biggio G, et al. International Union of Pharmacology. XV. Subtypes of gamma-aminobutyric acidA receptors: classification on the basis of subunit structure and receptor function. Pharmacol Rev. 1998;50(2):291–313.PubMed
24.
25.
Krasowski MD, Jenkins A, Flood P, Kung AY, Hopfinger AJ, Harrison NL. General anesthetic potencies of a series of propofol analogs correlate with potency for potentiation of gamma-aminobutyric acid (GABA) current at the GABA(A) receptor but not with lipid solubility. J Pharmacol Exp Ther. 2001;297(1):338–51.PubMed
26.
27.
Sanna E, Murgia A, Casula A, Biggio G. Differential subunit dependence of the actions of the general anesthetics alphaxalone and etomidate at gamma-aminobutyric acid type A receptors expressed in Xenopus laevis oocytes. Mol Pharmacol. 1997;51(3):484–90.PubMed
28.
Hales TG, Lambert JJ. The actions of propofol on inhibitory amino-acid receptors of bovine adrenomedullary chromaffin cells and rodent central neurons. Br J Pharmacol. 1991;104(3):619–28.PubMedCentralPubMedCrossRef
29.
Machu TK, Harris RA. Alcohols and anesthetics enhance the function of 5-hydroxytryptamine(3) receptors expressed in Xenopus laevis oocytes. J Pharmacol Exp Ther. 1994;271(2):898–905.PubMed
30.
Yamakura T, Sakimura K, Shimoji K, Mishina M. Effects of propofol on various Ampa-selective, kainate-selective and NMDA-selective glutamate-receptor channels expressed in Xenopus oocytes. Neurosci Lett. 1995;188(3):187–90. doi:10.​1016/​0304-3940(95)11431-U.PubMedCrossRef
31.
Simons PJ, Cockshott ID, Douglas EJ, Gordon EA, Hopkins K, Rowland M. Disposition in male-volunteers of a subanaesthetic intravenous dose of an oil in water emulsion of propofol-C-14. Xenobiotica. 1988;18(4):429–40.PubMedCrossRef
32.
Hiraoka H, Yamamoto K, Okano N, Morita T, Goto F, Horiuchi R. Changes in drug plasma concentrations of an extensively bound and highly extracted drug, propofol, in response to altered plasma binding. Clin Pharmacol Ther. 2004;75(4):324–30. doi:10.​1016/​j.​clpt.​2003.​12.​004.PubMedCrossRef
33.
34.
35.
36.
Schuttler J, Ihmsen H. Population pharmacokinetics of propofol: a multicenter study. Anesthesiology. 2000;92(3):727–38.PubMedCrossRef
37.
Rigby-Jones AE, Nolan JA, Priston MJ, Wright PM, Sneyd JR, Wolf AR. Pharmacokinetics of propofol infusions in critically ill neonates, infants, and children in an intensive care unit. Anesthesiology. 2002;97(6):1393–400.PubMedCrossRef
38.
Al-Jahdari WS, Yamamoto K, Hiraoka H, Nakamura K, Goto F, Horiuchi R. Prediction of total propofol clearance based on enzyme activities in microsomes from human kidney and liver. Eur J Clin Pharmacol. 2006;62(7):527–33. doi:10.​1007/​s00228-006-0130-2.PubMedCrossRef
39.
Tateishi T, Nakura H, Asoh M, Watanabe M, Tanaka M, Kumai T, et al. A comparison of hepatic cytochrome P450 protein expression between infancy and postinfancy. Life Sci. 1997;61(26):2567–74.PubMedCrossRef
40.
Allegaert K, Peeters MY, Verbesselt R, Tibboel D, Naulaers G, de Hoon JN, et al. Inter-individual variability in propofol pharmacokinetics in preterm and term neonates. Br J Anaesth. 2007;99(6):864–70. doi:10.​1093/​bja/​aem294.PubMedCrossRef
41.
42.
43.
44.
45.
Kataria BK, Ved SA, Nicodemus HF, Hoy GR, Lea D, Dubois MY, et al. The pharmacokinetics of propofol in children using three different data analysis approaches. Anesthesiology. 1994;80(1):104–22.PubMedCrossRef
46.
47.
48.
Jeleazcov C, Ihmsen H, Schmidt J, Ammon C, Schwilden H, Schuttler J, et al. Pharmacodynamic modelling of the bispectral index response to propofol-based anaesthesia during general surgery in children. Br J Anaesth. 2008;100(4):509–16. doi:10.​1093/​bja/​aem408.PubMedCrossRef
49.
Rigouzzo A, Girault L, Louvet N, Servin F, De-Smet T, Piat V, et al. The relationship between bispectral index and propofol during target-controlled infusion anesthesia: a comparative study between children and young adults. Anesth Analga. 2008;106(4):1109–16. doi:10.​1213/​ane.​0b013e318164f388​.CrossRef
50.
51.
Coppens M, Van Limmen JG, Schnider T, Wyler B, Bonte S, Dewaele F, et al. Study of the time course of the clinical effect of propofol compared with the time course of the predicted effect-site concentration: performance of three pharmacokinetic-dynamic models. Br J Anaesth. 2010;104(4):452–8. doi:10.​1093/​bja/​aeq028.PubMedCrossRef
52.
53.
Bjornsson MA, Norberg A, Kalman S, Karlsson MO, Simonsson US. A two-compartment effect site model describes the bispectral index after different rates of propofol infusion. J Pharmacokinet Pharmacodyn. 2010;37(3):243–55. doi:10.​1007/​s10928-010-9157-1.PubMedCrossRef
54.
Wiczling P, Bienert A, Sobczynski P, Hartmann-Sobczynska R, Bieda K, Marcinkowska A, et al. Pharmacokinetics and pharmacodynamics of propofol in patients undergoing abdominal aortic surgery. Pharmacol Rep. 2012;64(1):113–22.PubMedCrossRef
55.
McFarlan CS, Anderson BJ, Short TG. The use of propofol infusions in paediatric anaesthesia: a practical guide. Paediatr Anaesth. 1999;9(3):209–16.PubMed
56.
57.
58.
59.
60.
Igarashi T, Nagata O, Iwakiri H, Ikeda M, Uezono S, Ozaki M. Two cases of intraoperative awareness during intravenous anesthesia with propofol in morbidly obese patients. Masui. 2002;51(11):1243–7.PubMed
61.
62.
Upton RN, Ludbrook GL, Grant C, Martinez AM. Cardiac output is a determinant of the initial concentrations of propofol after short-infusion administration. Anesth Analg. 1999;89(3):545–52.PubMed
63.
64.
65.
Cortinez LI, Anderson BJ, Penna A, Olivares L, Munoz HR, Holford NH, et al. Influence of obesity on propofol pharmacokinetics: derivation of a pharmacokinetic model. Br J Anaesth. 2010;105(4):448–56. doi:10.​1093/​bja/​aeq195.PubMedCrossRef
66.
67.
68.
Chidambaran V, Venkatasubramanian R, Sadhasivam S, Esslinger H, Cox S, Diepstraten J, et al. Population pharmacokinetic-pharmacodynamic modeling and dosing simulation of propofol maintenance anesthesia in severely obese adolescents. Paediatr Anaesth. 2015;. doi:10.​1111/​pan.​12684.PubMed
69.
Diepstraten J, Chidambaran V, Sadhasivam S, Blusse van Oud-Alblas HJ, Inge T, van Ramshorst B, et al. An integrated population pharmacokinetic meta-analysis of propofol in morbidly obese and nonobese adults, adolescents, and children. CPT Pharmacometrics Syst Pharmacol. 2013;2:e73. doi:10.​1038/​psp.​2013.​47.PubMedCentralPubMedCrossRef
70.
Grossherr M, Hengstenberg A, Meier T, Dibbelt L, Igl BW, Ziegler A, et al. Propofol concentration in exhaled air and arterial plasma in mechanically ventilated patients undergoing cardiac surgery. Br J Anaesth. 2009;102(5):608–13. doi:10.​1093/​bja/​aep053.PubMedCrossRef
71.
Perl T, Carstens E, Hirn A, Quintel M, Vautz W, Nolte J, et al. Determination of serum propofol concentrations by breath analysis using ion mobility spectrometry. Br J Anaesth. 2009;103(6):822–7. doi:10.​1093/​bja/​aep312.PubMedCrossRef
72.
73.
Marsh B, White M, Morton N, Kenny GN. Pharmacokinetic model driven infusion of propofol in children. Br J Anaesth. 1991;67(1):41–8.PubMedCrossRef
74.
Gepts E, Camu F, Cockshott ID, Douglas EJ. Disposition of propofol administered as constant rate intravenous infusions in humans. Anesth Analg. 1987;66(12):1256–63.PubMedCrossRef
75.
Absalom A, Amutike D, Lal A, White M, Kenny GN. Accuracy of the ‘Paedfusor’ in children undergoing cardiac surgery or catheterization. Br J Anaesth. 2003;91(4):507–13.PubMedCrossRef
76.
Coppens MJ, Eleveld DJ, Proost JH, Marks LA, Van Bocxlaer JF, Vereecke H, et al. An evaluation of using population pharmacokinetic models to estimate pharmacodynamic parameters for propofol and bispectral index in children. Anesthesiology. 2011;115(1):83–93. doi:10.​1097/​ALN.​0b013e31821a8d80​.PubMedCrossRef
77.
Schnider TW, Minto CF, Gambus PL, Andresen C, Goodale DB, Shafer SL, et al. The influence of method of administration and covariates on the pharmacokinetics of propofol in adult volunteers. Anesthesiology. 1998;88(5):1170–82.PubMedCrossRef
78.
79.
80.
Vuyk J, Mertens MJ, Olofsen E, Burm AG, Bovill JG. Propofol anesthesia and rational opioid selection: determination of optimal EC50-EC95 propofol-opioid concentrations that assure adequate anesthesia and a rapid return of consciousness. Anesthesiology. 1997;87(6):1549–62.PubMedCrossRef
81.
82.
Reves JG, Glass P, Lubarsky DA. Intravenous anesthestics. Miller’s anesthesia. 7th ed. Philadelphia: Churchill Livingstone; 2010.
83.
84.
Vuyk J, Sitsen E, Reekers M. Intravenous anesthestics. Miller’s. 8th ed. Philadelphia: Elsevier; 2014.
85.
Williams GD, Jones TK, Hanson KA, Morray JP. The hemodynamic effects of propofol in children with congenital heart disease. Anesth Analg. 1999;89(6):1411–6.PubMed
86.
Cullen PM, Turtle M, Prys-Roberts C, Way WL, Dye J. Effect of propofol anesthesia on baroreflex activity in humans. Anesth Analg. 1987;66(11):1115–20.PubMedCrossRef
87.
88.
89.
90.
Matta BF, Lam AM, Strebel S, Mayberg TS. Cerebral pressure autoregulation and carbon dioxide reactivity during propofol-induced EEG suppression. Br J Anaesth. 1995;74(2):159–63.PubMedCrossRef
91.
Noterman J, Berre J, Vandesteene A, Brotchi J. Monitoring of intracranial pressure during the postoperative period of aneurysms. Neurochirurgie. 1988;34(3):161–3.PubMed
92.
Bacon RC, Razis PA. The effect of propofol sedation in pregnancy on neonatal condition. Anaesthesia. 1994;49(12):1058–60.PubMedCrossRef
93.
Lanigan C, Sury M, Bingham R, Howard R, Mackersie A. Neurological sequelae in children after prolonged propofol infusion. Anaesthesia. 1992;47(9):810–1.PubMedCrossRef
94.
Trotter C, Serpell MG. Neurological sequelae in children after prolonged propofol infusion. Anaesthesia. 1992;47(4):340–2.PubMedCrossRef
95.
Bendiksen A, Larsen LM. Convulsions, ataxia and hallucinations following propofol. Acta Anaesthesiol Scand. 1998;42(6):739–41.PubMedCrossRef
96.
97.
Fredriksson A, Ponten E, Gordh T, Eriksson P. Neonatal exposure to a combination of N-methyl-D-aspartate and gamma-aminobutyric acid type A receptor anesthetic agents potentiates apoptotic neurodegeneration and persistent behavioral deficits. Anesthesiology. 2007;107(3):427–36. doi:10.​1097/​01.​anes.​0000278892.​62305.​9c.PubMedCrossRef
98.
99.
100.
Ergun R, Akdemir G, Sen S, Tasci A, Ergungor F. Neuroprotective effects of propofol following global cerebral ischemia in rats. Neurosurg Rev. 2002;25(1–2):95–8.PubMedCrossRef
101.
Bayona NA, Gelb AW, Jiang Z, Wilson JX, Urquhart BL, Cechetto DF. Propofol neuroprotection in cerebral ischemia and its effects on low-molecular-weight antioxidants and skilled motor tasks. Anesthesiology. 2004;100(5):1151–9.PubMedCrossRef
102.
Engelhard K, Werner C, Eberspacher E, Pape M, Stegemann U, Kellermann K, et al. Influence of propofol on neuronal damage and apoptotic factors after incomplete cerebral ischemia and reperfusion in rats: a long-term observation. Anesthesiology. 2004;101(4):912–7.PubMedCrossRef
103.
104.
Devlin VJ, Schwartz DM. Intraoperative neurophysiologic monitoring during spinal surgery. J Am Acad Orthopaed Surg. 2007;15(9):549–60.
105.
Sloan TB, Heyer EJ. Anesthesia for intraoperative neurophysiologic monitoring of the spinal cord. J Clin Neurophysiol. 2002;19(5):430–43.PubMedCrossRef
106.
Fung NY, Hu Y, Irwin MG, Chow BE, Yuen MY. Comparison between sevoflurane/remifentanil and propofol/remifentanil anaesthesia in providing conditions for somatosensory evoked potential monitoring during scoliosis corrective surgery. Anaesth Intensive Care. 2008;36(6):779–85.PubMed
107.
108.
Dahan A, Nieuwenhuijs DJ, Olofsen E. Influence of propofol on the control of breathing. Adv Exp Med Biol. 2003;523:81–92.PubMedCrossRef
109.
Goodman NW, Black AM, Carter JA. Some ventilatory effects of propofol as sole anaesthetic agent. Br J Anaesth. 1987;59(12):1497–503.PubMedCrossRef
110.
Jonsson MM, Lindahl SG, Eriksson LI. Effect of propofol on carotid body chemosensitivity and cholinergic chemotransduction. Anesthesiology. 2005;102(1):110–6.PubMedCrossRef
111.
Eastwood PR, Platt PR, Shepherd K, Maddison K, Hillman DR. Collapsibility of the upper airway at different concentrations of propofol anesthesia. Anesthesiology. 2005;103(3):470–7.PubMedCrossRef
112.
Nakayama M, Murray PA. Ketamine preserves and propofol potentiates hypoxic pulmonary vasoconstriction compared with the conscious state in chronically instrumented dogs. Anesthesiology. 1999;91(3):760–71.PubMedCrossRef
113.
Nishiyama T, Hanaoka K. Propofol-induced bronchoconstriction: two case reports. Anesth Analg. 2001;93(3):645–6.PubMedCrossRef
114.
115.
116.
Wheeler DS, Vaux KK, Ponaman ML, Poss BW. The safe and effective use of propofol sedation in children undergoing diagnostic and therapeutic procedures: experience in a pediatric ICU and a review of the literature. Pediatr Emerg Care. 2003;19(6):385–92.PubMedCrossRef
117.
118.
Koroglu A, Teksan H, Sagir O, Yucel A, Toprak HI, Ersoy OM. A comparison of the sedative, hemodynamic, and respiratory effects of dexmedetomidine and propofol in children undergoing magnetic resonance imaging. Anesthes Analg. 2006;103(1):63–7. doi:10.​1213/​01.​ANE.​0000219592.​82598.​AA.CrossRef
119.
Wu J, Mahmoud M, Schmitt M, Hossain M, Kurth D. Comparison of propofol and dexmedetomedine techniques in children undergoing magnetic resonance imaging. Paediatr Anaesth. 2014;24(8):813–8. doi:10.​1111/​pan.​12408.PubMedCrossRef
120.
Mahmoud M, Jung D, Salisbury S, McAuliffe J, Gunter J, Patio M, et al. Effect of increasing depth of dexmedetomidine and propofol anesthesia on upper airway morphology in children and adolescents with obstructive sleep apnea. J Clin Anesth. 2013;25(7):529–41. doi:10.​1016/​j.​jclinane.​2013.​04.​011.PubMedCrossRef
121.
Cravero JP, Beach ML, Blike GT, Gallagher SM, Hertzog JH, Pediatric Sedation Research Consortium. The incidence and nature of adverse events during pediatric sedation/anesthesia with propofol for procedures outside the operating room: a report from the Pediatric Sedation Research Consortium. Anesthes Analg. 2009;108(3):795–804. doi:10.​1213/​ane.​0b013e31818fc334​.CrossRef
122.
Kamat PP, McCracken CE, Gillespie SE, Fortenberry JD, Stockwell JA, Cravero JP, et al. Pediatric critical care physician-administered procedural sedation using propofol: a report from the Pediatric Sedation Research Consortium Database. Pediatr Crit Care Med. 2015;16(1):11–20. doi:10.​1097/​PCC.​0000000000000273​.PubMedCrossRef
123.
Mallory MD, Baxter AL, Yanosky DJ, Cravero JP, Pediatric Sedation Research Consortium. Emergency physician-administered propofol sedation: a report on 25,433 sedations from the pediatric sedation research consortium. Ann Emerg Med. 2011;57(5):462–8 e1. doi:10.​1016/​j.​annemergmed.​2011.​03.​008.
124.
125.
126.
127.
Lerman J. Surgical and patient factors involved in postoperative nausea and vomiting. Br J Anaesth. 1992;69(7 Suppl 1):24S–32S.PubMedCrossRef
128.
Gan TJ, Glass PS, Howell ST, Canada AT, Grant AP, Ginsberg B. Determination of plasma concentrations of propofol associated with 50% reduction in postoperative nausea. Anesthesiology. 1997;87(4):779–84.PubMedCrossRef
129.
Erdem AF, Yoruk O, Alici HA, Cesur M, Atalay C, Altas E, et al. Subhypnotic propofol infusion plus dexamethasone is more effective than dexamethasone alone for the prevention of vomiting in children after tonsillectomy. Paediatr Anaesth. 2008;18(9):878–83. doi:10.​1111/​j.​1460-9592.​2008.​02675.​x.PubMedCrossRef
130.
Erdem AF, Yoruk O, Silbir F, Alici HA, Cesur M, Dogan N, et al. Tropisetron plus subhypnotic propofol infusion is more effective than tropisetron alone for the prevention of vomiting in children after tonsillectomy. Anaesth Intensive Care. 2009;37(1):54–9.PubMed
131.
Unlugenc H, Guler T, Gunes Y, Isik G. Comparative study of the antiemetic efficacy of ondansetron, propofol and midazolam in the early postoperative period. Eur J Anaesthesiol. 2004;21(1):60–5.PubMedCrossRef
132.
133.
Tramer M, Moore A, McQuay H. Meta-analytic comparison of prophylactic antiemetic efficacy for postoperative nausea and vomiting: propofol anaesthesia vs omitting nitrous oxide vs total i.v. anaesthesia with propofol. Br J Anaesth. 1997;78(3):256–9.PubMedCrossRef
134.
Tramer M, Moore A, McQuay H. Propofol anaesthesia and postoperative nausea and vomiting: quantitative systematic review of randomized controlled studies. Br J Anaesth. 1997;78(3):247–55.PubMedCrossRef
135.
136.
137.
138.
Chandler JR, Myers D, Mehta D, Whyte E, Groberman MK, Montgomery CJ, et al. Emergence delirium in children: a randomized trial to compare total intravenous anesthesia with propofol and remifentanil to inhalational sevoflurane anesthesia. Paediatr Anaesth. 2013;23(4):309–15. doi:10.​1111/​pan.​12090.PubMedCrossRef
139.
140.
Cameron E, Johnston G, Crofts S, Morton NS. The minimum effective dose of lignocaine to prevent injection pain due to propofol in children. Anaesthesia. 1992;47(7):604–6.PubMedCrossRef
141.
Picard P, Tramer MR. Prevention of pain on injection with propofol: a quantitative systematic review. Anesth Analg. 2000;90(4):963–9.PubMedCrossRef
142.
143.
Briggs LP, Clarke RS, Dundee JW, Moore J, Bahar M, Wright PJ. Use of di-isopropyl phenol as main agent for short procedures. Br J Anaesth. 1981;53(11):1197–202.PubMedCrossRef
144.
Hannallah RS, Baker SB, Casey W, McGill WA, Broadman LM, Norden JM. Propofol: effective dose and induction characteristics in unpremedicated children. Anesthesiology. 1991;74(2):217–9.PubMedCrossRef
145.
Scott RP, Saunders DA, Norman J. Propofol: clinical strategies for preventing the pain of injection. Anaesthesia. 1988;43(6):492–4.PubMedCrossRef
146.
Stark RD, Binks SM, Dutka VN, O’Connor KM, Arnstein MJ, Glen JB. A review of the safety and tolerance of propofol (‘Diprivan’). Postgrad Med J. 1985;61(Suppl 3):152–6.PubMed
147.
Klement W, Arndt JO. Pain on injection of propofol: effects of concentration and diluent. Br J Anaesth. 1991;67(3):281–4.PubMedCrossRef
148.
Doenicke AW, Roizen MF, Rau J, Kellermann W, Babl J. Reducing pain during propofol injection: the role of the solvent. Anesth Analg. 1996;82(3):472–4.PubMed
149.
Nakane M, Iwama H. A potential mechanism of propofol-induced pain on injection based on studies using nafamostat mesilate. Br J Anaesth. 1999;83(3):397–404.PubMedCrossRef
150.
Stokes DN, Robson N, Hutton P. Effect of diluting propofol on the incidence of pain on injection and venous sequelae. Br J Anaesth. 1989;62(2):202–3.PubMedCrossRef
151.
McCrirrick A, Hunter S. Pain on injection of propofol: the effect of injectate temperature. Anaesthesia. 1990;45(6):443–4.PubMedCrossRef
152.
Barker P, Langton JA, Murphy P, Rowbotham DJ. Effect of prior administration of cold saline on pain during propofol injection: a comparison with cold propofol and propofol with lignocaine. Anaesthesia. 1991;46(12):1069–70.PubMedCrossRef
153.
Fletcher GC, Gillespie JA, Davidson JA. The effect of temperature upon pain during injection of propofol. Anaesthesia. 1996;51(5):498–9.PubMedCrossRef
154.
Valtonen M, Iisalo E, Kanto J, Tikkanen J. Comparison between propofol and thiopentone for induction of anaesthesia in children. Anaesthesia. 1988;43(8):696–9.PubMedCrossRef
155.
McCulloch MJ, Lees NW. Assessment and modification of pain on induction with propofol (Diprivan). Anaesthesia. 1985;40(11):1117–20.PubMedCrossRef
156.
Nicol ME, Moriarty J, Edwards J, Robbie DS, A’Hern RP. Modification of pain on injection of propofol: a comparison between lignocaine and procaine. Anaesthesia. 1991;46(1):67–9.PubMedCrossRef
157.
158.
Nyman Y, von Hofsten K, Georgiadi A, Eksborg S, Lonnqvist PA. Propofol injection pain in children: a prospective randomized double-blind trial of a new propofol formulation versus propofol with added lidocaine. Br J Anaesth. 2005;95(2):222–5. doi:10.​1093/​bja/​aei156.PubMedCrossRef
159.
Rochette A, Hocquet AF, Dadure C, Boufroukh D, Raux O, Lubrano JF, et al. Avoiding propofol injection pain in children: a prospective, randomized, double-blinded, placebo-controlled study. Br J Anaesth. 2008;101(3):390–4. doi:10.​1093/​bja/​aen169.PubMedCrossRef
160.
161.
162.
Ang BL. Prolonged cutaneous sequelae after intra-arterial injection of propofol. Singapore Med J. 1998;39(3):124–6.PubMed
163.
Hepner DL, Castells MC. Anaphylaxis during the perioperative period. Anesth Analg. 2003;97(5):1381–95.PubMedCrossRef
164.
165.
166.
167.
Ring J. Allergy in practice. Berlin: Springer; 2005.
168.
Lizaso BMTL, Sainz SA, Puebla AMJ. Cutaneous response to Diprivan (propofol) and Intralipid in patients with leguminous and egg allergy. Rev Esp Alergol Immunol Clin. 1998;13:153–7.
169.
170.
de Leon-Casasola OA, Weiss A, Lema MJ. Anaphylaxis due to propofol. Anesthesiology. 1992;77(2):384–6.PubMedCrossRef
171.
Rigoulet M, Devin A, Averet N, Vandais B, Guerin B. Mechanisms of inhibition and uncoupling of respiration in isolated rat liver mitochondria by the general anesthetic 2,6-diisopropylphenol. Eur J Biochem. 1996;241(1):280–5.PubMedCrossRef
172.
Wallace JJ, Perndt H, Skinner M. Anaesthesia and mitochondrial disease. Paediatr Anaesth. 1998;8(3):249–54.PubMedCrossRef
173.
Branca D, Roberti MS, Vincenti E, Scutari G. Uncoupling effect of the general anesthetic 2,6-diisopropylphenol in isolated rat liver mitochondria. ArchBiochem Biophysics. 1991;290(2):517–21.CrossRef
174.
175.
176.
177.
Muravchick S, Levy RJ. Clinical implications of mitochondrial dysfunction. Anesthesiology. 2006;105(4):819–37.PubMedCrossRef
178.
179.
180.
Farag E, Deboer G, Cohen BH, Niezgoda J. Metabolic acidosis due to propofol infusion. Anesthesiology. 2005;102(3):697–8.
181.
Parke TJ, Stevens JE, Rice AS, Greenaway CL, Bray RJ, Smith PJ, et al. Metabolic acidosis and fatal myocardial failure after propofol infusion in children: five case reports. BMJ. 1992;305(6854):613–6.PubMedCentralPubMedCrossRef
182.
183.
Felmet K, Nguyen T, Clark RS, Orr D, Carcillo J. The FDA warning against prolonged sedation with propofol in children remains warranted. Pediatrics. 2003;112(4):1002–3 (author reply-3).
184.
Cornfield DN, Tegtmeyer K, Nelson MD, Milla CE, Sweeney M. Continuous propofol infusion in 142 critically ill children. Pediatrics. 2002;110(6):1177–81.PubMedCrossRef
185.
186.
Diaz JH, Prabhakar A, Urman RD, Kaye AD. Propofol infusion syndrome: a retrospective analysis at a level 1 trauma center. Critical Care Res Pract. 2014;2014:346968. doi:10.​1155/​2014/​346968.
187.
188.
Holzki J, Aring C, Gillor A. Death after re-exposure to propofol in a 3-year-old child: a case report. Paediatr Anaesth. 2004;14(3):265–70.PubMedCrossRef
189.
190.
Culp KE, Augoustides JG, Ochroch AE, Milas BL. Clinical management of cardiogenic shock associated with prolonged propofol infusion. Anesth Analg. 2004;99(1):221–6.PubMedCrossRef
191.
Crawford MW, Dodgson BG, Holtby HH, Roy WL. Propofol syndrome in children. CMAJ = journal de l’Association medicale canadienne. 2003;168(6):669.
192.
193.
Fodale V, La Monaca E. Propofol infusion syndrome: an overview of a perplexing disease. Drug Saf. 2008;31(4):293–303.PubMedCrossRef
194.
195.
Orser BA, Bertlik M, Wang LY, MacDonald JF. Inhibition by propofol (2,6 di-isopropylphenol) of the N-methyl-d-aspartate subtype of glutamate receptor in cultured hippocampal neurones. Br J Pharmacol. 1995;116(2):1761–8.PubMedCentralPubMedCrossRef
196.
Kingston S, Mao L, Yang L, Arora A, Fibuch EE, Wang JQ. Propofol inhibits phosphorylation of N-methyl-d-aspartate receptor NR1 subunits in neurons. Anesthesiology. 2006;104(4):763–9.PubMedCrossRef
197.
Anker-Moller E, Spangsberg N, Arendt-Nielsen L, Schultz P, Kristensen MS, Bjerring P. Subhypnotic doses of thiopentone and propofol cause analgesia to experimentally induced acute pain. Br J Anaesth. 1991;66(2):185–8.PubMedCrossRef
198.
Merrill AW, Barter LS, Rudolph U, Eger EI, 2nd, Antognini JF, Carstens MI, et al. Propofol’s effects on nociceptive behavior and spinal c-fos expression after intraplantar formalin injection in mice with a mutation in the gamma-aminobutyric acid-type(A) receptor beta3 subunit. Anesth Analg. 2006;103(2):478–83. doi: 10.​1213/​01.​ane.​0000223847.​50233.​1b.
199.
200.
201.
202.
203.
Boccara G, Mann C, Pouzeratte Y, Bellavoir A, Rouvier A, Colson P. Improved postoperative analgesia with isoflurane than with propofol anaesthesia. Can J Anaesth. 1998;45(9):839–42. doi:10.​1007/​BF03012216.PubMedCrossRef
204.
205.
206.
207.
Wang QY, Cao JL, Zeng YM, Dai TJ. GABAA receptor partially mediated propofol-induced hyperalgesia at superspinal level and analgesia at spinal cord level in rats. Acta Pharmacol Sinica. 2004;25(12):1619–25.
208.
Bercker S, Bert B, Bittigau P, Felderhoff-Muser U, Buhrer C, Ikonomidou C, et al. Neurodegeneration in newborn rats following propofol and sevoflurane anesthesia. Neurotoxicity Res. 2009;16(2):140–7. doi:10.​1007/​s12640-009-9063-8.CrossRef
209.
Ikonomidou C, Bosch F, Miksa M, Bittigau P, Vockler J, Dikranian K, et al. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science. 1999;283(5398):70–4.PubMedCrossRef
210.
211.
212.
213.
Cortinez LI, De la Fuente N, Eleveld DJ, Oliveros A, Crovari F, Sepulveda P, et al. Performance of propofol target-controlled infusion models in the obese: pharmacokinetic and pharmacodynamic analysis. Anesth Analg. 2014;119(2):302–10. doi:10.​1213/​ANE.​0000000000000317​.PubMedCrossRef
214.
Metadata
Title
Propofol: A Review of its Role in Pediatric Anesthesia and Sedation
Authors
Vidya Chidambaran
Andrew Costandi
Ajay D’Mello
Publication date
01-07-2015
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 7/2015
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.1007/s40263-015-0259-6

Other articles of this Issue 7/2015

CNS Drugs 7/2015 Go to the issue

Review Article

The Prevalence, Measurement, and Treatment of the Cognitive Dimension/Domain in Major Depressive Disorder

Original Research Article

Antipsychotic Drug Use and the Risk of Seizures: Follow-up Study with a Nested Case–Control Analysis

Leading Article

The Therapeutic Potential of α7 Nicotinic Acetylcholine Receptor (α7 nAChR) Agonists for the Treatment of the Cognitive Deficits Associated with Schizophrenia

Adis Diagnostic Evaluation

[18F]Florbetaben: A Review in β-Amyloid PET Imaging in Cognitive Impairment

Current Opinion

Prevention Studies in Alzheimer’s Disease: Progress Towards the Development of New Therapeutics

Review Article

Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis